Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

Koji Miyahara, Kazuhiro Nouso, Yuki Morimoto, Yasuto Takeuchi, Hiroaki Hagihara, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Yasuhiro Miyake, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Shouta Iwadou, Yoshiyuki Kobayashi, Koichi Takaguchi, Yoshitaka Takuma, Hiroyuki Takabatake, Kohsaku Sakaguchi, Kazuhide Yamamoto, Shin ichi FujiokaToshiya Osawa, Kazuya Kariyama, Junichi Toshimori, Haruhiko Kobashi, Hirokazu Miyatake, Shuji Uematsu, Ryoichi Okamoto, Yasuyuki Araki, Masafumi Tatsukawa, Kazuhisa Yabushita, Toshinari Shimoe, Tatsuro Sakata, Toshihiko Kaneyoshi, Manabi Miyashita, Yasuhiro Makino, Akio Moriya, Masaharu Ando, Nobuyuki Baba, Tomonori Seno, Takuya Nagano, Eiji Matsumoto, Hiroki Takayama

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. Methods: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n=23) and stopped (n=13) sorafenib at first radiological PD. Results: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P=0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P=0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P=0.085). Conclusion: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.

Original languageEnglish
Pages (from-to)296-301
Number of pages6
JournalHepatology Research
Volume44
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Hepatocellular Carcinoma
Survival
Growth
sorafenib
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • Sorafenib
  • Survival beyond first progression

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Miyahara, K., Nouso, K., Morimoto, Y., Takeuchi, Y., Hagihara, H., Kuwaki, K., ... Takayama, H. (2014). Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatology Research, 44(3), 296-301. https://doi.org/10.1111/hepr.12123

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. / Miyahara, Koji; Nouso, Kazuhiro; Morimoto, Yuki; Takeuchi, Yasuto; Hagihara, Hiroaki; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Iwadou, Shouta; Kobayashi, Yoshiyuki; Takaguchi, Koichi; Takuma, Yoshitaka; Takabatake, Hiroyuki; Sakaguchi, Kohsaku; Yamamoto, Kazuhide; Fujioka, Shin ichi; Osawa, Toshiya; Kariyama, Kazuya; Toshimori, Junichi; Kobashi, Haruhiko; Miyatake, Hirokazu; Uematsu, Shuji; Okamoto, Ryoichi; Araki, Yasuyuki; Tatsukawa, Masafumi; Yabushita, Kazuhisa; Shimoe, Toshinari; Sakata, Tatsuro; Kaneyoshi, Toshihiko; Miyashita, Manabi; Makino, Yasuhiro; Moriya, Akio; Ando, Masaharu; Baba, Nobuyuki; Seno, Tomonori; Nagano, Takuya; Matsumoto, Eiji; Takayama, Hiroki.

In: Hepatology Research, Vol. 44, No. 3, 2014, p. 296-301.

Research output: Contribution to journalArticle

Miyahara, K, Nouso, K, Morimoto, Y, Takeuchi, Y, Hagihara, H, Kuwaki, K, Ohnishi, H, Ikeda, F, Miyake, Y, Nakamura, S, Shiraha, H, Takaki, A, Iwadou, S, Kobayashi, Y, Takaguchi, K, Takuma, Y, Takabatake, H, Sakaguchi, K, Yamamoto, K, Fujioka, SI, Osawa, T, Kariyama, K, Toshimori, J, Kobashi, H, Miyatake, H, Uematsu, S, Okamoto, R, Araki, Y, Tatsukawa, M, Yabushita, K, Shimoe, T, Sakata, T, Kaneyoshi, T, Miyashita, M, Makino, Y, Moriya, A, Ando, M, Baba, N, Seno, T, Nagano, T, Matsumoto, E & Takayama, H 2014, 'Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma', Hepatology Research, vol. 44, no. 3, pp. 296-301. https://doi.org/10.1111/hepr.12123
Miyahara, Koji ; Nouso, Kazuhiro ; Morimoto, Yuki ; Takeuchi, Yasuto ; Hagihara, Hiroaki ; Kuwaki, Kenji ; Ohnishi, Hideki ; Ikeda, Fusao ; Miyake, Yasuhiro ; Nakamura, Shinichiro ; Shiraha, Hidenori ; Takaki, Akinobu ; Iwadou, Shouta ; Kobayashi, Yoshiyuki ; Takaguchi, Koichi ; Takuma, Yoshitaka ; Takabatake, Hiroyuki ; Sakaguchi, Kohsaku ; Yamamoto, Kazuhide ; Fujioka, Shin ichi ; Osawa, Toshiya ; Kariyama, Kazuya ; Toshimori, Junichi ; Kobashi, Haruhiko ; Miyatake, Hirokazu ; Uematsu, Shuji ; Okamoto, Ryoichi ; Araki, Yasuyuki ; Tatsukawa, Masafumi ; Yabushita, Kazuhisa ; Shimoe, Toshinari ; Sakata, Tatsuro ; Kaneyoshi, Toshihiko ; Miyashita, Manabi ; Makino, Yasuhiro ; Moriya, Akio ; Ando, Masaharu ; Baba, Nobuyuki ; Seno, Tomonori ; Nagano, Takuya ; Matsumoto, Eiji ; Takayama, Hiroki. / Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. In: Hepatology Research. 2014 ; Vol. 44, No. 3. pp. 296-301.
@article{98b03f29da234f69af69069d5d34e6ad,
title = "Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma",
abstract = "Aim: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. Methods: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n=23) and stopped (n=13) sorafenib at first radiological PD. Results: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P=0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P=0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P=0.085). Conclusion: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.",
keywords = "Hepatocellular carcinoma, Sorafenib, Survival beyond first progression",
author = "Koji Miyahara and Kazuhiro Nouso and Yuki Morimoto and Yasuto Takeuchi and Hiroaki Hagihara and Kenji Kuwaki and Hideki Ohnishi and Fusao Ikeda and Yasuhiro Miyake and Shinichiro Nakamura and Hidenori Shiraha and Akinobu Takaki and Shouta Iwadou and Yoshiyuki Kobayashi and Koichi Takaguchi and Yoshitaka Takuma and Hiroyuki Takabatake and Kohsaku Sakaguchi and Kazuhide Yamamoto and Fujioka, {Shin ichi} and Toshiya Osawa and Kazuya Kariyama and Junichi Toshimori and Haruhiko Kobashi and Hirokazu Miyatake and Shuji Uematsu and Ryoichi Okamoto and Yasuyuki Araki and Masafumi Tatsukawa and Kazuhisa Yabushita and Toshinari Shimoe and Tatsuro Sakata and Toshihiko Kaneyoshi and Manabi Miyashita and Yasuhiro Makino and Akio Moriya and Masaharu Ando and Nobuyuki Baba and Tomonori Seno and Takuya Nagano and Eiji Matsumoto and Hiroki Takayama",
year = "2014",
doi = "10.1111/hepr.12123",
language = "English",
volume = "44",
pages = "296--301",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

AU - Miyahara, Koji

AU - Nouso, Kazuhiro

AU - Morimoto, Yuki

AU - Takeuchi, Yasuto

AU - Hagihara, Hiroaki

AU - Kuwaki, Kenji

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Miyake, Yasuhiro

AU - Nakamura, Shinichiro

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Iwadou, Shouta

AU - Kobayashi, Yoshiyuki

AU - Takaguchi, Koichi

AU - Takuma, Yoshitaka

AU - Takabatake, Hiroyuki

AU - Sakaguchi, Kohsaku

AU - Yamamoto, Kazuhide

AU - Fujioka, Shin ichi

AU - Osawa, Toshiya

AU - Kariyama, Kazuya

AU - Toshimori, Junichi

AU - Kobashi, Haruhiko

AU - Miyatake, Hirokazu

AU - Uematsu, Shuji

AU - Okamoto, Ryoichi

AU - Araki, Yasuyuki

AU - Tatsukawa, Masafumi

AU - Yabushita, Kazuhisa

AU - Shimoe, Toshinari

AU - Sakata, Tatsuro

AU - Kaneyoshi, Toshihiko

AU - Miyashita, Manabi

AU - Makino, Yasuhiro

AU - Moriya, Akio

AU - Ando, Masaharu

AU - Baba, Nobuyuki

AU - Seno, Tomonori

AU - Nagano, Takuya

AU - Matsumoto, Eiji

AU - Takayama, Hiroki

PY - 2014

Y1 - 2014

N2 - Aim: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. Methods: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n=23) and stopped (n=13) sorafenib at first radiological PD. Results: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P=0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P=0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P=0.085). Conclusion: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.

AB - Aim: We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease (PD), and whether it prolongs patients' survival. Methods: The size of metastatic lesions was measured in 36 patients with advanced HCC treated with sorafenib. The tumor growth rates before and after radiological PD as well as survival were compared between the patients who continued (n=23) and stopped (n=13) sorafenib at first radiological PD. Results: The growth rate did not differ between before and after PD in patients who continued sorafenib, while it increased after PD in patients who stopped sorafenib at PD (P=0.002). Survival beyond first progression was longer in patients who continued sorafenib than in those who stopped it at PD (P=0.012), and this tendency was observed even when the analysis was limited to Child-Pugh class A patients (P=0.085). Conclusion: Sorafenib administration beyond first radiological PD could continuously suppress HCC growth and may have survival benefit.

KW - Hepatocellular carcinoma

KW - Sorafenib

KW - Survival beyond first progression

UR - http://www.scopus.com/inward/record.url?scp=84895135279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895135279&partnerID=8YFLogxK

U2 - 10.1111/hepr.12123

DO - 10.1111/hepr.12123

M3 - Article

AN - SCOPUS:84895135279

VL - 44

SP - 296

EP - 301

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 3

ER -